Company: AEMD
Filing Date: 2025-08-29
Form Type: S-1/A
Source: 0001683168-25-006537
Chunk: 44

Company: AETHLON MEDICAL INC
Filing Date: 2025-08-29
Form: S-1/A
Chunk 44
---
 list the warrants or pre-funded warrants on any national securities exchange or other nationally recognized
trading system, including The Nasdaq Capital Market. Without an active trading market, the liquidity of the warrants and pre-funded warrants
will be limited.

We will not receive any meaningful amount of additional funds upon the exercise of the Pre-Funded Warrants.

Each
Pre-Funded Warrant will be exercisable until it is fully exercised and by means of payment of the nominal cash purchase price upon exercise.
Accordingly, we will not receive any meaningful additional funds upon the exercise of the Pre-Funded Warrants.

Significant holders or beneficial holders of shares of our common stock may not be permitted to exercise the Pre-Funded Warrants that they hold.

A holder
of the Pre-Funded Warrants will not be entitled to exercise any portion of any Pre-Funded Warrant that, upon giving effect to such exercise,
would cause: (i) the aggregate number of shares of our common stock beneficially owned by such holder (together with its affiliates) to
exceed 4.99% (or, upon election of holder, 9.99%) of the number of shares of our common stock outstanding immediately after giving effect
to the exercise; or (ii) the combined voting power of our securities beneficially owned by such holder (together with its affiliates)
to exceed 4.99% (or, upon election of holder, 9.99%) of the combined voting power of all of our securities outstanding immediately after
giving effect to the exercise, as such percentage ownership is determined in accordance with the terms of the Pre-Funded Warrants. As
a result, you may not be able to exercise your Pre-Funded Warrants for shares of our common stock at a time when it would be financially
beneficial for you to do so. In such a circumstance, you could seek to sell your Pre-Funded Warrants to realize value, but you may be
unable to do so in the absence of an established trading market and due to applicable transfer restrictions.

| 24 |

<div align='center'>SPECIAL NOTE REGARDING FORWARD-LOOKING STATEMENTS</div>

This prospectus and the documents
incorporated herein by reference contain forward-looking statements. The forward-looking statements are contained principally in the sections
entitled “Summary,” “Risk Factors,” “Management’s Discussion and Analysis of Financial Condition and
Results of Operations” and “Business” in this prospectus or the documents incorporated herein by reference